RxDoctor Payments Data

Daniel Tanase, MD

Pulmonary Disease · West Chester, OHNPI 1770513178

Payments from drug & device makers

$1,293in general payments, 2019–2025

Across 43 payments — averaging $30.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Hill-rom Services, Inc$700
  • GSK$316
  • AstraZeneca$47
  • Verona Pharma, Inc.$38
  • Insmed, Inc.$37
  • Boston Scientific$33
  • plus $122 from 6 others

What the payments were for

  • Speaking & faculty fees$70054%
  • Food & beverage$55943%
  • Education$353%

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,293 in reported general payments places this provider in the 45th percentile of 571 pulmonary disease providers in Ohio.

See all pulmonary disease providers in Ohio

Medicare billing

Part B allowed, 2024
$82,241
Medicare patients
389
Services billed
848

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter337$276,188
TezspireTezepelumab-Ekko26$162,626
Dupixent SyringeDupilumab31$124,633
Breo ElliptaFluticasone/Vilanterol169$94,985
Spiriva RespimatTiotropium Bromide59$46,351
Spiriva HandihalerTiotropium Bromide45$28,473
Stiolto RespimatTiotropium Br/Olodaterol Hcl46$28,083
SymbicortBudesonide/Formoterol Fumarate76$23,172
Bevespi AerosphereGlycopyrrolate/Formoterol Fum41$16,063
Incruse ElliptaUmeclidinium Bromide44$15,659
DuleraMometasone/Formoterol25$14,691
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$8,410
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$7,424
Albuterol Sulfate HfaAlbuterol Sulfate219$5,876
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate36$5,841

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta, Arnuity Ellipta$316$399,330582 claims
AstraZenecaTezspire, Symbicort, Bevespi Aerosphere, Breztri Aerosphere, Pulmicort Flexhaler$47$213,770167 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 571 pulmonary disease providers in Ohio.

Other pulmonary disease in West Chester

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →